A phase I clinical trial targeting 22 patients with multiple melanoma metastases was conducted using hypofractionation radiotherapy (8 GyX3) combined with anti-CTLA4 antibody ipril monoclonal antibody. The gene discussed is CTLA4; the disease is melanoma.